To show the PSMA PET/CT superior performance for staging prostate cancer, a meta-analysis found PSMA PET/CT had a pooled sensitivity of 77% (95% CI: 71–82%) and specificity of 97% (95% CI: 95–98%) for detecting lymph node metastases [57]. The gene discussed is FOLH1; the disease is metastatic malignant neoplasm in the lymph nodes.